Transcatheter aortic valve implantation: the shape matters

EuroIntervention 2023;19:539-540. DOI: 10.4244/EIJ-E-23-00039

Won-Keun Kim
Won-Keun Kim1,2,3, MD, PhD; Andreas Holzamer4, MD
1. Department of Cardiology and Cardiac Surgery, Kerckhoff Heart Center, Bad Nauheim, Germany; 2. Department of Cardiology, Justus Liebig University Giessen, Giessen, Germany; 3. German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Bad Nauheim, Germany; 4. Department of Cardiothoracic Surgery, University of Regensburg Heart Center, Regensburg, Germany
Transcatheter aortic valve implantation (TAVI) has brought about a paradigm change in the treatment of patients with severe aortic stenosis. There is a growing body of evidence and continuous advancement in the field of transcatheter valve intervention, including expansion to indications other than aortic stenosis, such as pure aortic regurgitation (AR). Currently, the only device approved for transcatheter treatment of pure AR is the Trilogy valve (JenaValve). However, logistical issues and strict anatomical requirements impede its unrestricted use, which is why alternative valve systems must be considered for this subset of patients. Overall, the results of TAVI for ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Learning the lessons (again) of the challenges of conducting sham-controlled device trials in hypertension

Latest news